Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 2, 2014, Pages 71-86

  Sanoh, Seigo ^a   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

chimeric mice; hepatocytes; metabolism; pharmacokinetics; prediction

Indexed keywords

AMOSULALOL; CYTOCHROME P450 3A; DENAGLIPTIN; DRUG METABOLIZING ENZYME; FK 3453; GDC 0834; GW 695634; IBUPROFEN; METANDIENONE; MIDAZOLAM; SB 406725; THALIDOMIDE; TROGLITAZONE; UNCLASSIFIED DRUG; WARFARIN; ZALEPLON; DRUG;

CELL ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; NONHUMAN; REVIEW; ANIMAL; CELL TRANSPLANTATION; CHIMERA; CYTOLOGY; LIVER; METABOLISM; MOUSE; PHARMACOKINETICS;

ANIMALS; CELL TRANSPLANTATION; CHIMERA; HEPATOCYTES; HUMANS; LIVER; MICE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84896692068     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1864     Document Type: Review

References (86)

1. Kola I, Landis J,. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3 (8): 711-715. (Pubitemid 39173511)
2. Arrowsmith J,. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011; 10 (5): 328-329. doi: 10.1038/nrd3439.
3. Beedham C,. The role of non-P450 enzymes in drug oxidation. Review. Pharm World Sci 1997; 19 (6): 255-263. (Pubitemid 27511692)
4. i/AUC) ratios. Drug Metab Dispos 2004; 32 (11): 1201-1208. (Pubitemid 39410902)
5. Martignoni M, Groothuis GM, de Kanter R,. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Review. Expert Opin Drug Metab Toxicol 2006; 2 (6): 875-894. (Pubitemid 44911538)
6. Dalvie D, Obach RS, Kang P, et al,. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009; 22 (2): 357-368. doi: 10.1021/tx8004357.
7. Chiou WL, Buehler PW,. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 2002; 19 (6): 868-874. (Pubitemid 34686748)
8. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T,. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 2010; 38 (2): 308-316. doi: 10.1124/dmd.109.028829.
9. Chiou WL, Jeong HY, Chung SM, Wu TC,. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 2000; 17 (2): 135-140. (Pubitemid 30158360)
10. Obach RS, Baxter JG, Liston TE, et al,. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283 (1): 46-58. (Pubitemid 27438945)
11. Obach RS,. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27 (11): 1350-1359.
12. Nagilla R, Frank KA, Jolivette LJ, Ward KW,. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 2006; 53 (2): 106-116.
13. Brown HS, Griffin M, Houston JB,. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007; 35 (2): 293-301. (Pubitemid 46148743)
14. Fagerholm U,. Prediction of human pharmacokinetics-evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 2007; 59 (6): 803-828. (Pubitemid 47051093)
15. Stringer R, Nicklin PL, Houston JB,. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 2008; 38 (10): 1313-1329. doi: 10.1080/00498250802446286.
16. Chiba M, Ishii Y, Sugiyama Y,. Prediction of hepatic clearance in human from in vitro data for successful drug development. Review. AAPS J 2009; 11 (2): 262-276. doi: 10.1208/s12248-009-9103-6.
17. Hallifax D, Foster JA, Houston JB,. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 2010; 27 (10): 2150-2161. doi: 10.1007/s11095-010-0218-3.
18. Ekins S, Obach RS,. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. J Pharmacol Exp Ther 2000; 295 (2): 463-473.
19. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA,. Prediction of human pharmacokinetics using physiologically based modeling a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35 (10): 1766-1780. (Pubitemid 47481568)
20. Tabata K, Hamakawa N, Sanoh S, Terashita S, Teramura T,. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research. Eur J Drug Metab Pharmacokinet 2009; 34 (2): 117-128.
21. Paixão P, Gouveia LF, Morais JA,. Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks. Eur J Pharm Sci 2010; 39 (5): 310-321. doi: 10.1016/j.ejps.2009.12.007.
22. Huang L, Berry L, Ganga S, et al,. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 2010; 38 (2): 223-231. doi: 10.1124/dmd.109.029066.
23. Tateno C, Yoshizane Y, Saito N, et al,. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165 (3): 901-912. (Pubitemid 39129297)
24. Hasegawa M, Kawai K, Mitsui T, et al,. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 2011; 405 (3): 405-410. doi: 10.1016/j.bbrc.2011.01.042.
25. Katoh M, Matsui T, Nakajima M, et al,. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004; 32 (12): 1402-1410. (Pubitemid 39564560)
26. Katoh M, Matsui T, Okumura H, et al,. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2005; 33 (9): 1333-1340. (Pubitemid 41196976)
27. Nishimura M, Yoshitsugu H, Yokoi T, et al,. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 2005; 35 (9): 877-890. (Pubitemid 41759173)
28. Aoki K, Kashiwagura Y, Horie T, et al,. Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 2006; 21 (4): 277-285.
29. Katoh M, Yokoi T,. Application of chimeric mice with humanized liver for predictive ADME. Review. Drug Metab Rev 2007; 39 (1): 145-157.
30. Kitamura S, Nitta K, Tayama Y, et al,. Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36 (7): 1202-1205. doi: 10.1124/dmd.107.019075. (Pubitemid 351929332)
31. Yamasaki C, Kataoka M, Kato Y, et al,. In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 2010; 25 (6): 539-550.
32. Okumura H, Katoh M, Sawada T, et al,. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 2007; 97 (2): 533-538. (Pubitemid 47073867)
33. Katoh M, Sawada T, Soeno Y, et al,. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2007; 96 (2): 428-437. (Pubitemid 46363572)
34. Katoh M, Watanabe M, Tabata T, et al,. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 2005; 35 (9): 863-875. (Pubitemid 41759172)
35. Emoto C, Yamato Y, Sato Y, et al,. Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 2008; 38 (3): 239-248. doi: 10.1080/00498250701760159. (Pubitemid 351264445)
36. Hasegawa M, Tahara H, Inoue R, Kakuni M, Tateno C, Ushiki J,. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab Dispos 2012; 40 (3): 474-480. doi: 10.1124/dmd.111.042754.
37. Yamazaki H, Suemizu H, Murayama N, et al,. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol 2013; 26 (3): 486-489. doi: 10.1021/tx400008g.
38. Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S,. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36 (12): 2429-2433. doi: 10.1124/dmd.108.022830.
39. 3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 2009; 24 (2): 153-160.
40. Samuelsson K, Pickup K, Sarda S, et al,. Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers. Xenobiotica 2012; 42 (11): 1128-1137. doi: 10.3109/00498254.2012.689888.
41. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL,. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Review. Am J Gastroenterol 2000; 95 (1): 272-276. (Pubitemid 30041572)
42. Smith MT,. Mechanisms of troglitazone hepatotoxicity. Review. Chem Res Toxicol 2003; 16 (6): 679-687.
43. Schulz-Utermoehl T, Sarda S, Foster JR, et al,. Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 2012; 42 (6): 503-517. doi: 10.3109/00498254.2011.640716.
44. Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, Koup JR,. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J Clin Pharmacol 1999; 39 (9): 920-926. (Pubitemid 30644027)
45. Kawai K, Kawasaki-Tokui Y, Odaka T, et al,. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 1997; 47 (4): 356-368. (Pubitemid 27207306)
46. Kawai K, Tsurut F, Iwabuchi H, et al,. Disposition and metabolism of the oral antidiabetic drug toroglitazone in monkeys. Xenobio Metabol Dispos 2000; 15: 89-100.
47. Kakuni M, Morita M, Matsuo K, et al,. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett 2012; 214 (1): 9-18. doi: 10.1016/j.toxlet.2012.08.001.
48. Lootens L, Meuleman P, Pozo OJ, Van Eenoo P, Leroux-Roels G, Delbeke FT,. uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem 2009; 55 (10): 1783-1793. doi: 10.1373/clinchem.2008.119396.
49. Kamimura H, Nakada N, Suzuki K, et al,. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Review. Drug Metab Pharmacokinet 2010; 25 (3): 223-235.
50. Sasaki H, Kamimura H, Kaniwa H, Kawamura S, Takaichi M, Yokoshima T,. Disposition and metabolism of amosulalol hydrochloride a new combined alpha- and beta-Adrenoceptor blocking agent, in rats, dogs and monkeys. Xenobiotica 1984; 14 (8): 621-631. (Pubitemid 14030239)
51. Suzuki K, Kamimura H,. Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. Biol Pharm Bull 2007; 30 (8): 1580-1585.
52. Kamimura H, Sasaki H, Kawamura S,. Metabolism of amosulalol hydrochloride in man: quantitative comparison with laboratory animals. Xenobiotica 1985; 15 (5): 413-420. (Pubitemid 15036878)
53. De Serres M, Bowers G, Boyle G, et al,. Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 2011; 41 (6): 464-475. doi: 10.3109/00498254.2011. 560295.
54. Liu L, Halladay JS, Shin Y, et al,. Significant species difference in amide hydrolysis of GDC-0834 a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos 2011; 39 (10): 1840-1849. doi: 10.1124/dmd.111.040840.
55. Yamazaki H, Suemizu H, Shimizu M, et al,. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol 2012; 25 (2): 274-276. doi: 10.1021/tx300009j.
56. Utoh R, Tateno C, Kataoka M, et al,. Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice. Am J Pathol 2010; 177 (2): 654-665. doi: 10.2353/ajpath.2010.090430.
57. Yamazaki H, Kuribayashi S, Inoue T, et al,. Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-A]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 2010; 23 (1): 152-158. doi: 10.1021/tx900323a.
58. Kuribayashi S, Goto K, Naito S, Kamataki T, Yamazaki H,. Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5- trimethoxybenzoylamino)pyrazolo[1,5-A]pyrimidine. Chem Res Toxicol 2009; 22 (2): 323-331. doi: 10.1021/tx8003592.
59. Sanoh S, Horiguchi A, Sugihara K, et al,. Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes. Drug Metab Dispos 2012; 40 (12): 2267-2272. doi: 10.1124/dmd.112.047555.
60. Shirley MA, Guan X, Kaiser DG, Halstead GW, Baillie TA,. Taurine conjugation of ibuprofen in humans and in rat liver in vitro. Relationship to metabolic chiral inversion. J Pharmacol Exp Ther 1994; 269 (3): 1166-1175. (Pubitemid 24204201)
61. Kepp DR, Sidelmann UG, Tjørnelund J, Hansen SH,. Simultaneous quantitative determination of the major phase I and II metabolites of ibuprofen in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr B Biomed Sci Appl 1997; 696 (2): 235-241. (Pubitemid 27387449)
62. Sugawara Y, Fujihara M, Miura Y, Hayashida K, Takahashi T,. Studies on the fate of naproxen. II. Metabolic fate in various animals and man. Chem Pharm Bull (Tokyo) 1978; 26 (11): 3312-3321. (Pubitemid 9074852)
63. Beedham C,. Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Review. Prog Med Chem 1987; 24: 85-127.
64. Garattini E, Mendel R, Romão MJ, Wright R, Terao M,. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Review. Biochem J 2003; 372 (1): 15-32. (Pubitemid 36609603)
65. Garattini E, Terao M,. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 2011; 43 (3): 374-386. doi: 10.3109/03602532.2011.560606.
66. Zhang X, Liu HH, Weller P, et al,. In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 2011; 11 (1): 15-24. doi: 10.1038/tpj.2010.8.
67. Akabane T, Tanaka K, Irie M, Terashita S, Teramura T,. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 2011; 41 (5): 372-384. doi: 10.3109/00498254.2010.549970.
68. Diamond S, Boer J, Maduskuie TP Jr, Falahatpisheh N, Li Y, Yeleswaram S,. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 2010; 38 (8): 1277-1285. doi: 10.1124/dmd.110.032375.
69. Zientek M, Jiang Y, Youdim K, Obach RS,. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 2010; 38 (8): 1322-1327. doi: 10.1124/dmd.110.033555.
70. Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB,. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 2012; 40 (2): 267-275. doi: 10.1124/dmd.111. 042861.
71. Akabane T, Gerst N, Masters JN, Tamura K,. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica 2012; 42 (9): 863-871. doi: 10.3109/00498254. 2012.670736.
72. Sanoh S, Nozaki K, Murai H, Terashita S, Teramura T, Ohta S,. Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 2012; 40 (1): 76-82. doi: 10.1124/dmd.111.041954.
73. Moriyasu A, Sugihara K, Nakatani K, Ohta S, Kitamura S,. In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab Pharmacokinet 2006; 21 (6): 485-491.
74. Sugihara K, Tayama Y, Shimomiya K, Yoshimoto D, Ohta S, Kitamura S,. Estimation of aldehyde oxidase activity in vivo from conversion ratio of N1-methylnicotinamide to pyridones, and intraspecies variation of the enzyme activity in rats. Drug Metab Dispos 2006; 34 (2): 208-212. (Pubitemid 43145022)
75. Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, Tanaka Y,. Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica 2007; 37 (7): 709-716. (Pubitemid 47057125)
76. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA,. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 2002; 32 (10): 835-847. (Pubitemid 35155519)
77. Tanoue C, Sugihara K, Uramaru N, et al,. Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica 2013; 43 (11): 956-62. doi: 10.3109/00498254.2013. 788232.
78. Garattini E, Fratelli M, Terao M,. The mammalian aldehyde oxidase gene family. Hum Genomics 2009; 4 (2): 119-130.
79. Kitamura S, Sugihara K, Nakatani K, et al,. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 1999; 48 (6): 607-611. (Pubitemid 30043806)
80. Al-Salmy HS,. Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 2001; 51 (4): 249-253. (Pubitemid 32848156)
81. Hartmann T, Terao M, Garattini E, et al,. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 2012; 40 (5): 856-864. doi: 10.1124/dmd.111.043828.
82. Sanoh S, Horiguchi A, Sugihara K, et al,. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 2012; 40 (2): 322-328. doi: 10.1124/dmd.111.040923.
83. Pang KS, Rowland M,. Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5 (6): 625-653. (Pubitemid 8253670)
84. Xiao G, Bohnert T, Black C, Klunk L, Gan LS,. Evaluation of chimeric mice with humanized liver to predict human intrinsic clearance of drug molecules at preclinical phase. Drug Metab Rev 2010; 42 (S1): 60.
85. Hutzler JM, Obach RS, Dalvie D, Zientek MA,. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 2013; 9 (2): 153-168. doi: 10.1517/17425255.2013.738668.
86. Tateno C, Miya F, Wake K, et al,. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 2013; 93 (1): 54-71. doi: 10.1038/labinvest.2012.158